Momentum continues to be strong in the 2 main divisions despite currency headwinds. The spectre of CIT is now behind the Group and focus can be fully on Technical Plastics and LED Technologies with the added potential of Carclo Diagnostic Solutions (CDS). Within CDS, resources will now concentrate on the infectious disease and cardiac care tests where chances of commercialisation are more compelling. Discontinuation of the blood coagulation test leads to a £2.8m intangible impairment. On a P/E o ....
